[Topic efficacy of ialuronic acid associated with argentic sulphadiazine (Connettivina Plus) in the treatment of pressure sores: a prospective observational cohort study].
The aim of this observational study was to evaluate the efficacy, tolerability and methods of application of ialuronic acid associated with argentic sulphadiazine (Connettivina Plus) in routine clinical activity, on a target of "complex" patients with pressure sores, for the most realistic assessment possible. The study comprised 127 patients hospitalized between January 2006 and December 2007, who received ialuronic acid associated with argentic sulphadiazine in addition to the standard treatment. Inclusion criteria were th presence of at least one stage 2 or 3 pressure sore (NPUAP '89 classification), pressure sore that the researcher had already decided to treat using ialuronic acid associated with argentic sulphadiazine , according to hospital protocol, area of the lesion less than 25cm2, patient age 18 years or more, informed patient consensus. Patients with these characteristics were , however, excluded if they did not provide written consent or if they had one of the following: presence of pressure sores with escara, concomitant neoplastic disease, concomitant insulin-dependent diabetes or other pathologies that interfere with skin regeneration, allergic diasthesis (acclaimed or presumed) to ialuronic acid - argentic sulphadiazine, inability / refusal to undergo all the subsequent controls required by the study. Improvement or complete healing of the pressure sores was observed in 67% of patients at early follow-up (10 days), increasing to 76% and 87% at 20 and 35 day controls respectively. The Push tool further improved in patients who carried on treatment. Use of ialuronic acid associated with argentic sulphadiazine was effective for treating grade 2-3 pressure sores in patients with chronic lesions and its efficacy was confirmed in association with both advanced and traditional types of medication.